Anti-Prion Therapeutic Development: High-Throughput Screening and Validation
Overview
flowchart TD
experiments_prion_therapeutic_["prion-therapeutic-development"]
experiments_prion_therapeutic_["Anti-Prion"]
experiments_prion_therapeutic_ -->|"related to"| experiments_prion_therapeutic_
style experiments_prion_therapeutic_ fill:#81c784,stroke:#333,color:#000
experiments_prion_therapeutic_["High-Throughput"]
experiments_prion_therapeutic_ -->|"related to"| experiments_prion_therapeutic_
style experiments_prion_therapeutic_ fill:#81c784,stroke:#333,color:#000
experiments_prion_therapeutic_["Screening"]
experiments_prion_therapeutic_ -->|"related to"| experiments_prion_therapeutic_
style experiments_prion_therapeutic_ fill:#81c784,stroke:#333,color:#000
experiments_prion_therapeutic_["Validation"]
experiments_prion_therapeutic_ -->|"related to"| experiments_prion_therapeutic_
style experiments_prion_therapeutic_ fill:#81c784,stroke:#333,color:#000
style experiments_prion_therapeutic_ fill:#4fc3f7,stroke:#333,color:#000
...Anti-Prion Therapeutic Development: High-Throughput Screening and Validation
Overview
Mermaid diagram (expand to render)
This experiment aims to identify and develop [therapeutic agents](/therapeutics/) that can prevent [prion protein](/entities/prnp) conversion, clear existing [prion](/entities/prnp) aggregates, and ultimately rescue neuronal function in [prion disease](/diseases/). The study combines [high-throughput screening](/technologies/high-throughput-screening) with mechanism-focused validation to advance candidates toward clinical translation. This connects to the broader [anti-prion therapeutic development](/therapeutics/) literature and [prion-like propagation](/mechanisms/extracellular-vesicle-tnt-mediated-spreading-comparison) strategies.
Scientific Rationale
Current treatment for prion diseases is entirely supportive, with no disease-modifying therapies available. The discovery that antisense oligonucleotides (ASOs) can extend survival in prion-infected mice (Raymond et al., 2019) has renewed interest in therapeutic development. However, several key challenges remain:
Target selection: Should we target [PrP^C](/entities/prnp) expression, [PrP^Sc](/entities/prnp) formation, or [PrP^Sc](/entities/prnp) clearance?
Blood-brain barrier: Most therapeutic candidates fail to achieve adequate [CNS](/brain-regions/) penetration
Therapeutic window: When in disease course can intervention still provide benefit?
Safety: [PrP^C](/entities/prnp) has essential physiological functions—can we selectively target the pathological form?This experiment addresses these challenges through a systematic approach combining target-based and phenotype-based screening.
Hypothesis
Combination therapy targeting both [prion formation](/entities/prnp) (via [PrP^C](/entities/prnp) reduction) and [prion clearance](/mechanisms/prion-propagation-mechanism) (via aggregation blockers) will provide superior efficacy compared to single-mechanism approaches, with a therapeutic window extending into early symptomatic disease. This parallels [combination therapy](/mechanisms/pd-combination-therapy-matrix) strategies in [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease).
Experimental Design
Phase 1: High-Throughput Screening (Months 1-8)
Primary screen: Aggregation inhibitor library
- Screen 50,000 compounds using cell-based prion aggregation assay
- Use PK1 cells (mouse neuroblastoma with persistent prion infection)
- Readout: PrP^Sc levels via PK digestion and Western blot
- Counter-screen: Cytotoxicity in uninfected cells
Secondary screen: Repurposing library
- Screen 2,000 FDA-approved drugs
- Include CNS-penetrant compounds prioritized
- Test in multiple prion strains (RML, 22L, FDC)
Tertiary screen: ASO library
- Screen 200 ASO sequences targeting PRNP mRNA
- Test knockdown efficiency and duration
- Evaluate for splice-modulating ASOs
Phase 2: Mechanism-Focused Validation (Months 6-18)
Lead optimization:
- Test concentration-response for top 50 hits
- Evaluate blood-brain barrier penetration (in vitro PAMPA, in situ brain uptake)
- Assess duration of effect
Mechanism studies:
- Determine mode of action: aggregation blocker vs. clearance enhancer vs. production inhibitor
- Test in neurons (iPSC-derived) and astrocytes
- Evaluate effect on prion strains
Combination studies:
- Test synergistic combinations:
- ASO + aggregation blocker
- Aggregation blocker + clearance enhancer
- Triple combination
Phase 3: In Vivo Validation (Months 12-24)
Mouse efficacy studies:
- Test top 5 candidates in prion-infected mice (RML model)
- Routes of administration: ICV, IV, oral
- Endpoints: survival, clinical score, PrP^Sc burden, neuronal preservation
- Establish dose-response and therapeutic window
Safety assessment:
- GLP toxicology for top 2 candidates
- Off-target analysis
- Assessment of PrP^C knockdown effects
IND-enabling studies:
- Formulation development
- GMP manufacturing
- Regulatory pre- consultation
Expected Outcomes
Lead compounds: 5-10 candidates with in vivo efficacy
Clinical candidates: 1-2 ready for IND-enabling studies
Combination protocols: Optimized combination regimens
Biomarkers: PrP^Sc reduction as a surrogate endpointKey Metrics
| Metric | Target |
|--------|-------|
| Screen hits | ≥100 with >50% PrP^Sc reduction |
| Lead compounds | ≥5 with in vivo efficacy |
| Survival extension | ≥30% in mouse model |
| Therapeutic window | Benefit in early symptomatic disease |
Feasibility Assessment
- Technical feasibility: HIGH — established HTS platforms and prion mouse models
- Previous success: ASO approach showed 50% survival extension in mice
- Timeline: 24 months to identify clinical candidates
Cost Estimate
| Component | Cost (USD) |
|-----------|------------|
| HTS screening | $400,000 |
| Lead optimization | $300,000 |
| In vivo studies | $500,000 |
| Safety assessment | $350,000 |
| IND-enabling studies | $500,000 |
| Personnel (4 FTE × 2 years) | $600,000 |
| Total | $2,650,000 |
Risk Mitigation
- Risk: Poor BBB penetration → Mitigation: Prioritize CNS-penetrant compounds in screen
- Risk: Toxicity from PrP^C knockdown → Mitigation: Use ASOs with partial knockdown, test in PrP^+/+ and PrP^+/- models
- Risk: Strain variability limiting applicability → Mitigation: Test against multiple strains
Cross-Disease Therapeutic Connections
Anti-[prion](/entities/prnp) therapeutic strategies connect to [protein aggregation](/mechanisms/mutant-huntingtin-aggregation) therapeutics across [neurodegenerative diseases](/diseases/):
Similar Aggregation-Targeting Approaches
- [Anti-aggregation compounds](/therapeutics/aggregation-inhibitors-huntingtons): [Flupirtine](/therapeutics/aggregation-inhibitors-huntingtons), [HSP70](/proteins/hsp70-protein) modulators, [ Congo red](/therapeutics/aggregation-inhibitors-huntingtons) derivatives — tested across [prion](/entities/prnp), [α-synuclein](/proteins/alpha-synuclein), [tau](/proteins/tau), [HTT](/genes/htt)
- [Immunotherapy](/therapeutics/alpha-synuclein-antibodies): [Anti-prion antibodies](/therapeutics/anti-prion-antibodies), [anti-α-synuclein antibodies](/therapeutics/alpha-synuclein-antibodies), [anti-tau antibodies](/therapeutics/anti-tau-antibodies) — clear extracellular aggregates
- [ASOs](/therapeutics/antisense-oligonucleotides): [Tominersen](/therapeutics/tominersen) for [HD](/diseases/huntingtons), [ASOs targeting SOD1](/therapeutics/antisense-oligonucleotides) for [ALS](/diseases/amyotrophic-lateral-sclerosis), [BIIB080](/therapeutics/antisense-oligonucleotides) for [AD](/diseases/alzheimers-disease)
- [Small molecule degraders](/therapeutics/proteolysis-targeting-chimeras-neurodegeneration): [PROTACs](/therapeutics/proteolysis-targeting-chimeras-neurodegeneration) for [tau](/proteins/tau), [α-synuclein](/proteins/alpha-synuclein)
Key Proteins with Aggregation-Targeting Strategies
| Protein | Disease | Aggregation Mechanism | Therapeutic Approach |
|---------|---------|----------------------|----------------------|
| [PrP^Sc](/entities/prnp) | [Prion disease](/diseases/creutzfeldt-jakob-disease) | β-sheet conversion | [ASOs](/therapeutics/antisense-oligonucleotides), antibodies |
| [α-synuclein](/proteins/alpha-synuclein) | [PD](/diseases/parkinsons-disease), [DLB](/diseases/dementia-lewy-bodies) | NAC domain aggregation | [Immunotherapy](/therapeutics/alpha-synuclein-antibodies), [ASOs](/therapeutics/antisense-oligonucleotides) |
| [Tau](/proteins/tau) | [AD](/diseases/alzheimers-disease), [PSP](/diseases/progressive-supranuclear-palsy) | Microtubule-binding repeat domain | [Methylene blue](/therapeutics/methylene-blue-alzheimers), [ASOs](/therapeutics/antisense-oligonucleotides) |
| [mHTT](/genes/htt) | [Huntington's disease](/diseases/huntingtons) | Polyglutamine expansion | [ASOs](/therapeutics/antisense-oligonucleotides), [PROTACs](/therapeutics/proteolysis-targeting-chimeras-neurodegeneration) |
| [TDP-43](/proteins/tardbp) | [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia) | C-terminal domain aggregation | [ASOs](/therapeutics/antisense-oligonucleotides), [aggregation inhibitors](/therapeutics/aggregation-inhibitors-huntingtons) |
References
[Raymond et al., Antisense oligonucleotides extend survival of prion-infected mice (2019)](https://pubmed.ncbi.nlm.nih/31307935/)
[Caughey & Lansbury, Prion protein conversion (2003)](https://pubmed.ncbi.nlm.nih/12700375/)
[Prusiner, Prion disease therapy (2013)](https://pubmed.ncbi.nlm.nih/23550050/)
[Giles et al., Prion therapeutics (2020)](https://pubmed.ncbi.nlm.nih/32018404/)
[Kahana & Aguzzi, Prion disease therapeutics (2022)](https://pubmed.ncbi.nlm.nih/35644218/)Pathway Diagram
The following diagram shows the key molecular relationships involving prion-therapeutic-development discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)